Iron, HCV, and Liver Cancer: Hard Metal Setting the Pace?

Gastroenterology

Volumn 130, Issue 7, 2006, Pages 2229-2234

  Mueller, Sebastian ^a   Afdhal, Nezam H ^a   Schuppan, Detlef ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; REACTIVE OXYGEN METABOLITE;

CANCER RISK; CELL PROLIFERATION; DISEASE COURSE; DNA DAMAGE; EDITORIAL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOSURVEILLANCE; IRON OVERLOAD; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; MUTAGENESIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS VIRULENCE;

EID: 33744517652     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.05.006     Document Type: Editorial

References (70)

1. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., Shau W.Y., Chen D.S., and Taiwan Childhood Hepatoma Study Group. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336 (1997) 1855-1859
2. Annual report of the US Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network Transplant Data: 1988-1994. Richmond, USA: United Network for Organ Sharing and the Division of Organ Transplantation, Bureau of Health Resources Development.
3. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., and Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 34 (2001) 730-739
4. Hepatitis viruses. IARC monographs on the evaluation of the carcinogenic risks of humans (1994), International agency for research on cancer, Lyon
5. Arbuthnot P., and Kew M. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol 82 (2001) 77-100
6. Bruix J., Barrera J.M., Calvet X., Ercilla G., Costa J., Sanchez-Tapias J.M., Ventura M., Vall M., Bruguera M., Bru C., et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2 (1989) 1004-1006
7. Di Martino V., Rufat P., Boyer N., Renard P., Degos F., Martinot-Peignoux M., Matheron S., Le Moing V., Vachon F., Degott C., Valla D., and Marcellin P. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users. a long-term retrospective cohort study. Hepatology 34 (2001) 1193-1199
8. Bondini S., and Younossi Z.M. Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol 52 (2006) 135-143
9. Kamal S.M., Turner B., He Q., Rasenack J., Bianchi L., Al Tawil A., Nooman A., Massoud M., Koziel M.J., and Afdhal N.H. Progression of fibrosis in hepatitis C with and without schistosomiasis. correlation with serum markers of fibrosis. Hepatology 43 (2006) 771-779
10. Kazemi-Shirazi L., Datz C., Maier-Dobersberger T., Kaserer K., Hackl F., Polli C., Steindl P.E., Penner E., and Ferenci P. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 116 (1999) 127-134
11. Piperno A., Vergani A., Malosio I., Parma L., Fossati L., Ricci A., Bovo G., Boari G., and Mancia G. Hepatic iron overload in patients with chronic viral hepatitis. role of HFE gene mutations. Hepatology 28 (1998) 1105-1109
12. Alla V., and Bonkovsky H.L. Iron in nonhemochromatotic liver disorders. Semin Liver Dis 25 (2005) 461-472
13. Pirisi M., Scott C.A., Avellini C., Toniutto P., Fabris C., Soardo G., Beltrami C.A., and Bartoli E. Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations. Am J Clin Pathol 113 (2000) 546-554
14. Farinati F., Cardin R., De Maria N., Della Libera G., Marafin C., Lecis E., Burra P., Floreani A., Cecchetto A., and Naccarato R. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 22 (1995) 449-456
15. Pietrangelo A., Gualdi R., Casalgrandi G., Geerts A., De Bleser P., Montosi G., and Ventura E. Enhanced hepatic collagen type I mRNA expression into fat-storing cells in a rodent model of hemochromatosis. Hepatology 19 (1994) 714-721
16. Ramm G.A., Li S.C., Li L., Britton R.S., O'Neill R., Kobayashi Y., and Bacon B.R. Chronic iron overload causes activation of rat lipocytes in vivo. Am J Physiol 268 (1995) G451-G458
17. Ramm G.A., and Ruddell R.G. Hepatotoxicity of iron overload. mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis 25 (2005) 433-449
18. Kowdley K.V. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127 (2004) S79-S86
19. Deugnier Y.M., Guyader D., Crantock L., Lopez J.M., Turlin B., Yaouanq J., Jouanolle H., Campion J.P., Launois B., Halliday J.W., et al. Primary liver cancer in genetic hemochromatosis. a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 104 (1993) 228-234
20. Niederau C., Fischer R., Sonnenberg A., Stremmel W., Trampisch H.J., and Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 313 (1985) 1256-1262
21. Borgna-Pignatti C., Vergine G., Lombardo T., Cappellini M.D., Cianciulli P., Maggio A., Renda D., Lai M.E., Mandas A., Forni G., Piga A., and Bisconte M.G. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 124 (2004) 114-117
22. Mandishona E., MacPhail A.P., Gordeuk V.R., Kedda M.A., Paterson A.C., Rouault T.A., and Kew M.C. Dietary iron overload as a risk factor for hepatocellular carcinoma in black Africans. Hepatology 27 (1998) 1563-1566
23. Moyo V.M., Makunike R., Gangaidzo I.T., Gordeuk V.R., McLaren C.E., Khumalo H., Saungweme T., Rouault T., and Kiire C.F. African iron overload and hepatocellular carcinoma (HA-7-0-080). Eur J Haematol 60 (1998) 28-34
24. Fargion S., Stazi M.A., Fracanzani A.L., Mattioli M., Sampietro M., Tavazzi D., Bertelli C., Patriarca V., Mariani C., and Fiorelli G. Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma. Blood Cells Mol Dis 27 (2001) 505-511
25. Smith B.C., Gorve J., Guzail M.A., Day C.P., Daly A.K., Burt A.D., and Bassendine M.F. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 27 (1998) 1695-1699
26. Chapoutot C., Esslimani M., Joomaye Z., Ramos J., Perney P., Laurent C., Fabbro-Peray P., Larrey D., Domergue J., and Blanc F. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut 46 (2000) 711-714
27. Lauret E., Rodriguez M., Gonzalez S., Linares A., Lopez-Vazquez A., Martinez-Borra J., Rodrigo L., and Lopez-Larrea C. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 97 (2002) 1016-1021
28. Cauza E., Peck-Radosavljevic M., Ulrich-Pur H., Datz C., Gschwantler M., Schoniger-Hekele M., Hackl F., Polli C., Rasoul-Rockenschaub S., Muller C., Wrba F., Gangl A., and Ferenci P. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol 98 (2003) 442-447
29. Boige V., Castera L., de Roux N., Ganne-Carrie N., Ducot B., Pelletier G., Beaugrand M., and Buffet C. Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut 52 (2003) 1178-1181
30. Iwasa M., Kaito M., Ikoma J., Kobayashi Y., Tanaka Y., Higuchi K., Takeuchi K., Iwata K., Watanabe S., and Adachi Y. Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients. Hepatogastroenterology 49 (2002) 529-531
31. Yano M., Hayashi H., Yoshioka K., Kohgo Y., Saito H., Niitsu Y., Kato J., Iino S., Yotsuyanagi H., Kobayashi Y., Kawamura K., Kakumu S., Kaito M., Ikoma J., Wakusawa S., Okanoue T., Sumida Y., Kimura F., Kajiwara E., Sata M., and Ogata K. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C. a multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol 39 (2004) 570-574
32. Kato J., Kobune M., Nakamura T., Kuroiwa G., Takada K., Takimoto R., Sato Y., Fujikawa K., Takahashi M., Takayama T., Ikeda T., and Niitsu Y. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 61 (2001) 8697-8702
33. Schuppan D., Krebs A., Bauer M., and Hahn E.G. Hepatitis C and liver fibrosis. Cell Death Differ 10 Suppl 1 (2003) S59-S67
34. Schulze-Krebs A., Preimel D., Popov Y., Bartenschlager R., Lohmann V., Pinzani M., and Schuppan D. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 129 (2005) 246-258
35. Turlin B., Juguet F., Moirand R., Le Quilleuc D., Loreal O., Campion J.P., Launois B., Ramee M.P., Brissot P., and Deugnier Y. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 22 (1995) 446-450
36. Blanc J.F., De Ledinghen V., Bernard P.H., de Verneuil H., Winnock M., Le Bail B., Carles J., Saric J., Balabaud C., and Bioulac-Sage P. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol 32 (2000) 805-811
37. Bralet M.P., Regimbeau J.M., Pineau P., Dubois S., Loas G., Degos F., Valla D., Belghiti J., Degott C., and Terris B. Hepatocellular carcinoma occurring in nonfibrotic liver. epidemiologic and histopathologic analysis of 80 French cases. Hepatology 32 (2000) 200-204
38. Sherlock S. Diseases of the liver (1968), F.A. Davis Co, Philadelphia
39. Weintraub L.R., Goral A., Grasso J., Franzblau C., Sullivan A., and Sullivan S. Pathogenesis of hepatic fibrosis in experimental iron overload. Br J Haematol 59 (1985) 321-331
40. Barbaro G., Di Lorenzo G., Asti A., Ribersani M., Belloni G., Grisorio B., Filice G., and Barbarini G. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C. ultrastructural and biochemical findings. Am J Gastroenterol 94 (1999) 2198-2205
41. Valgimigli M., Valgimigli L., Trere D., Gaiani S., Pedulli G.F., Gramantieri L., and Bolondi L. Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. Free Radic Res 36 (2002) 939-948
42. Okuda M., Li K., Beard M.R., Showalter L.A., Scholle F., Lemon S.M., and Weinman S.A. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122 (2002) 366-375
43. Gong G., Waris G., Tanveer R., and Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 98 (2001) 9599-9604
44. Moriya K., Nakagawa K., Santa T., Shintani Y., Fujie H., Miyoshi H., Tsutsumi T., Miyazawa T., Ishibashi K., Horie T., Imai K., Todoroki T., Kimura S., and Koike K. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 61 (2001) 4365-4370
45. Huang H., Fujii H., Sankila A., Mahler-Araujo B.M., Matsuda M., Cathomas G., and Ohgaki H. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 155 (1999) 1795-1801
46. Green R., Esparza I., and Schreiber R. Iron inhibits the nonspecific tumoricidal activity of macrophages. A possible contributory mechanism for neoplasia in hemochromatosis. Ann N Y Acad Sci 526 (1988) 301-309
47. Deugnier Y., and Turlin B. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol 16 (2001) 491-494
48. Theurl I., Zoller H., Obrist P., Datz C., Bachmann F., Elliott R.M., and Weiss G. Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. J Infect Dis 190 (2004) 819-825
49. Fillebeen C., Rivas-Estilla A.M., Bisaillon M., Ponka P., Muckenthaler M., Hentze M.W., Koromilas A.E., and Pantopoulos K. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C virus. J Biol Chem 280 (2005) 9049-9057
50. Sievert W., Pianko S., Warner S., Bowden S., Simpson I., Bowden D., and Locarnini S. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy. a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol 97 (2002) 982-987
51. Liang T.J., and Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 127 (2004) S62-S71
52. Lerat H., Honda M., Beard M.R., Loesch K., Sun J., Yang Y., Okuda M., Gosert R., Xiao S.Y., Weinman S.A., and Lemon S.M. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122 (2002) 352-365
53. Disson O., Haouzi D., Desagher S., Loesch K., Hahne M., Kremer E.J., Jacquet C., Lemon S.M., Hibner U., and Lerat H. Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 126 (2004) 859-872
54. Moriya K., Yotsuyanagi H., Shintani Y., Fujie H., Ishibashi K., Matsuura Y., Miyamura T., and Koike K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78 (1997) 1527-1531
55. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., Matsuura Y., Kimura S., Miyamura T., and Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4 (1998) 1065-1067
56. Pigeon C., Turlin B., Iancu T.C., Leroyer P., Le Lan J., Deugnier Y., Brissot P., and Loreal O. Carbonyl-iron supplementation induces hepatocyte nuclear changes in BALB/CJ male mice. J Hepatol 30 (1999) 926-934
57. Carthew P., Dorman B.M., Edwards R.E., Francis J.E., and Smith A.G. A unique rodent model for both the cardiotoxic and hepatotoxic effects of prolonged iron overload. Lab Invest 69 (1993) 217-222
58. Zhou X.Y., Tomatsu S., Fleming R.E., Parkkila S., Waheed A., Jiang J., Fei Y., Brunt E.M., Ruddy D.A., Prass C.E., Schatzman R.C., O'Neill R., Britton R.S., Bacon B.R., and Sly W.S. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc. Natl. Acad. Sci U S A 95 (1998) 2492-2497
59. Furutani T., Hino H., Okuda M., Gondo T., Nishina S., Kitase A., Korenaga M., Xiao S.-Y., Weinman S.A., Lemon S.M., Sakaida I., and Okita K. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 130 (2006) 2087-2098
60. Rulyak S.J., Eng S.C., Patel K., McHutchison J.G., Gordon S.C., and Kowdley K.V. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am J Gastroenterol 100 (2005) 332-337
61. Hofer H., Osterreicher C., Jessner W., Penz M., Steindl-Munda P., Wrba F., and Ferenci P. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 40 (2004) 1018-1022
62. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., and Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
63. Laftah A.H., Sharma N., Brookes M.J., McKie A.T., Simpson R.J., Iqbal T.H., and Tselepis C. Tumour necrosis factor alpha causes hypoferraemia and reduced intestinal iron absorption in mice. Biochem J (2006) (in press).
64. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., and Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 (2004) 1271-1276
65. Mueller S. Iron regulatory protein 1 as a sensor of reactive oxygen species. Biofactors 24 (2005) 171-181
66. Lefkowitch J.H., Yee H.T., Sweeting J., Green P.H., and Magun A.M. Iron-rich foci in chronic viral hepatitis. Hum Pathol 29 (1998) 116-118
67. Perumalswami P., Kleiner D.E., Lutchman G., Heller T., Borg B., Park Y., Liang T.J., Hoofnagle J.H., and Ghany M.G. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 43 (2006) 780-787
68. Perlemuter G., Sabile A., Letteron P., Vona G., Topilco A., Chretien Y., Koike K., Pessayre D., Chapman J., Barba G., and Brechot C. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion. a model of viral-related steatosis. FASEB J 16 (2002) 185-194
69. Tanguy S., de Leiris J., Besse S., and Boucher F. Ageing exacerbates the cardiotoxicity of hydrogen peroxide through the Fenton reaction in rats. Mech Ageing Dev 124 (2003) 229-235
70. Machida K., Cheng K.T., Sung V.M., Shimodaira S., Lindsay K.L., Levine A.M., Lai M.Y., and Lai M.M. Hepatitis C virus induces a mutator phenotype. enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A 101 (2004) 4262-4267